Tikva Allocell
Develops engineered EBV-specific T-cell therapies intended to treat solid tumors, backed by Series A financing to advance its oncology program.
Overview
Tikva Allocell is developing engineered EBV-specific T-cell therapy for solid tumors, positioning the company in oncology cell therapy rather than AI. Its work targets patients with solid tumors where EBV-directed immune cells may offer a therapeutic approach, based on the financing announcement. The company closed an $8 million Series A round announced July 22, 2026, with proceeds earmarked to advance its engineered T-cell program. The funding context indicates an early-stage biotech focused on moving a lead cell-therapy platform forward.
Funding History
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Frequently Asked Questions
- How much funding does AI Funding track for Tikva Allocell?
- AI Funding tracks $8M for Tikva Allocell across 1 funding round in this database.
- What does Tikva Allocell do?
- Tikva Allocell is developing engineered EBV-specific T-cell therapy for solid tumors, positioning the company in oncology cell therapy rather than AI. Its work targets patients with solid tumors where EBV-directed immune cells may offer a therapeutic approach, based on the financing announcement. The company closed an $8 million Series A round announced July 22, 2026, with proceeds earmarked to advance its engineered T-cell program. The funding context indicates an early-stage biotech focused on moving a lead cell-therapy platform forward.
- Where is Tikva Allocell headquartered?
- Tikva Allocell is headquartered in San Francisco, CA.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.